You just read:

Shire's CINRYZE® (C1 esterase inhibitor [human]) Receives FDA Fast Track Designation for Investigation in the Treatment of Antibody Mediated Rejection (AMR) in Patients Receiving Kidney Transplants

News provided by

Shire plc

13 Oct, 2015, 12:00 BST